Targeting Minimal Residual Disease

被引：0

作者：

Chou, Yu-Ting ^{[1
,2
,3
]}

Allegakoen, Paul

Bivona, Trever G. ^{[1
,2
,3
,4
]}

机构：

[1] Univ Calif San Francisco, Dept Med, San Francisco, CA 94118 USA

[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94118 USA

[3] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94118 USA

[4] Chan Zuckerberg Biohub, San Francisco, CA USA

来源：

ANNUAL REVIEW OF CANCER BIOLOGY | 2025年 / 9卷

关键词：

minimal residual disease; MRD; drug tolerance; drug resistance; persistent; cells; circulating tumor DNA; ctDNA; ACUTE MYELOID-LEUKEMIA; CANCER STEM-CELLS; LUNG-CANCER; DRUG-RESISTANCE; TUMOR DORMANCY; LINEAGE PLASTICITY; FLOW-CYTOMETRY; INHIBITION; SURVIVAL; YAP;

D O I：

10.1146/annurev-cancerbio-070924-120742

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Minimal residual disease (MRD) represents a significant challenge in the treatment of various cancers, acting as a precursor to relapse and therapeutic resistance. This review discusses the clinical background of MRD, exploring its role as a critical determinant in patient outcomes. The persistence of MRD is attributed to several mechanisms, including Darwinian selection of preexisting resistant clones, Lamarckian induction of resistance traits, and pharmacologic resistance due to the tumor's intrinsic barriers to drugs and treatment limitations. These processes underscore MRD as the seed for long-term drug resistance, complicating treatment efficacy. Addressing MRD requires innovative therapeutic strategies, ranging from targeted therapies to novel drug combinations, aimed at eradicating these resilient cancer cells. By understanding and targeting MRD, we could improve patient prognoses and develop more effective cancer treatments. This review synthesizes current knowledge and emerging approaches in the quest to manage and eliminate MRD.

引用

页码：205 / 223

页数：19

共 118 条

[1] Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution [J].

Abbosh, Christopher ;

Birkbak, Nicolai J. ;

Wilson, Gareth A. ;

Jamal-Hanjani, Mariam ;

Constantin, Tudor ;

Salari, Raheleh ;

Le Quesne, John ;

Moore, David A. ;

Veeriah, Selvaraju ;

Rosenthal, Rachel ;

Marafioti, Teresa ;

Kirkizlar, Eser ;

Watkins, Thomas B. K. ;

McGranahan, Nicholas ;

Ward, Sophia ;

Martinson, Luke ;

Riley, Joan ;

Fraioli, Francesco ;

Al Bakir, Maise ;

Gronroos, Eva ;

Zambrana, Francisco ;

Endozo, Raymondo ;

Bi, Wenya Linda ;

Fennessy, Fiona M. ;

Sponer, Nicole ;

Johnson, Diana ;

Laycock, Joanne ;

Shafi, Seema ;

Czyzewska-Khan, Justyna ;

Rowan, Andrew ;

Chambers, Tim ;

Matthews, Nik ;

Turajlic, Samra ;

Hiley, Crispin ;

Lee, Siow Ming ;

Forster, Martin D. ;

Ahmad, Tanya ;

Falzon, Mary ;

Borg, Elaine ;

Lawrence, David ;

Hayward, Martin ;

Kolvekar, Shyam ;

Panagiotopoulos, Nikolaos ;

Janes, Sam M. ;

Thakrar, Ricky ;

Ahmed, Asia ;

Blackhall, Fiona ;

Summers, Yvonne ;

Hafez, Dina ;

Naik, Ashwini .

NATURE, 2017, 545 (7655) :446-+

[2] The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma [J].

Ahn, Antonio ;

Chatterjee, Aniruddha ;

Eccles, Michael R. .

MOLECULAR CANCER THERAPEUTICS, 2017, 16 (06) :1002-1009

[3]

Anderson NM, 2020, CURR BIOL, V30, pR921, DOI 10.1016/j.cub.2020.06.081

[4]

Aujla Amandeep, 2019, Stem Cell Investig, V6, P12, DOI 10.21037/sci.2019.05.02

[5]

Balaban NQ, 2019, NAT REV MICROBIOL, V17, P441, DOI 10.1038/s41579-019-0196-3

[6] Cancer cells enter dormancy after cannibalizing mesenchymal stem/stromal cells (MSCs) [J].

Bartosh, Thomas J. ;

Ullah, Mujib ;

Zeitouni, Suzanne ;

Beaver, Joshua ;

Prockop, Darwin J. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (42) :E6447-E6456

[7] The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance [J].

Beltran, Himisha ;

Hruszkewycz, Andrew ;

Scher, Howard I. ;

Hildesheim, Jeffrey ;

Isaacs, Jennifer ;

Yu, Evan Y. ;

Kelly, Kathleen ;

Lin, Daniel ;

Dicker, Adam ;

Arnold, Julia ;

Hecht, Toby ;

Wicha, Max ;

Sears, Rosalie ;

Rowley, David ;

White, Richard ;

Gulley, James L. ;

Lee, John ;

Meco, Maria Diaz ;

Small, Eric J. ;

Shen, Michael ;

Knudsen, Karen ;

Goodrich, David W. ;

Lotan, Tamara ;

Zoubeidi, Amina ;

Sawyers, Charles L. ;

Rudin, Charles M. ;

Loda, Massimo ;

Thompson, Timothy ;

Rubin, Mark A. ;

Tawab-Amiri, Abdul ;

Dahut, William ;

Nelson, Peter S. .

CLINICAL CANCER RESEARCH, 2019, 25 (23) :6916-6924

[8] TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer [J].

Bhola, Neil E. ;

Balko, Justin M. ;

Dugger, Teresa C. ;

Kuba, Maria Gabriela ;

Sanchez, Violeta ;

Sanders, Melinda ;

Stanford, Jamie ;

Cook, Rebecca S. ;

Arteaga, Carlos L. .

JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (03) :1348-1358

[9] A framework for understanding and targeting residual disease in oncogene-driven solid cancers [J].

Bivona, Trever G. ;

Doebele, Robert C. .

NATURE MEDICINE, 2016, 22 (05) :472-478

[10] NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer [J].

Blakely, Collin M. ;

Pazarentzos, Evangelos ;

Olivas, Victor ;

Asthana, Saurabh ;

Yan, Jenny Jiacheng ;

Tan, Irena ;

Hrustanovic, Gorjan ;

Chan, Elton ;

Lin, Luping ;

Neel, Dana S. ;

Newton, William ;

Bobb, Kathryn L. ;

Fouts, Timothy R. ;

Meshulam, Jeffrey ;

Gubens, Matthew A. ;

Jablons, David M. ;

Johnson, Jeffrey R. ;

Bandyopadhyay, Sourav ;

Krogan, Nevan J. ;

Bivona, Trever G. .

CELL REPORTS, 2015, 11 (01) :98-110

← 1 2 3 4 5 6 7 8 9 10 →